New drug combo aims to control rare lymphoma
NCT ID NCT01808599
Summary
This study is testing a treatment plan for a type of slow-growing cancer called MALT lymphoma. It combines two drugs, chlorambucil and rituximab, given as an initial intensive treatment. Patients who respond then receive rituximab alone as a long-term maintenance therapy for two years to try to keep the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AO SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
-
ARNAS Garibaldi Catania
Catania, Italy
-
Ancona
Ancona, Italy
-
Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia
Reggio Emilia, Italy
-
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy
-
Azienda Sanitaria AUSL6 Livorno
Livorno, Italy
-
Biella Ospedale degli Infermi
Biella, Italy
-
Centro di Riferimento Oncologico di Aviano
Aviano, Italy
-
Clermont Ferrand CHU Estaing
Estaing, France
-
Créteil Hopital Henri Mondor
Créteil, France
-
Dijon CHU Hopital le Bocage
Dijon, France
-
Ematologia Ospedale Businco (Cagliari)
Cagliari, Italy
-
Ematologia e CTMO Ospedale Bolzano
Bolzano, Italy
-
Genova Ematologia I H San Martino
Genova, Italy
-
Grenoble CHU Pontchaillou
Grenoble, France
-
IOSI - Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
-
IOV Padova
Padua, Italy
-
IRCCS/CROB Rionero in Vulture
Rionero in Vulture, Italy
-
Istituto Nazionale dei Tumori, Milano
Milan, Italy
-
Istituto Regina Elena, Roma, IFO
Roma, Italy
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Meldola, Italy
-
Lille CHRU Hopital Claude Dieu
Lille, France
-
Marseille Paoli Calmettes
Marseille, France
-
Milano Ospedale Policlinico
Milan, Italy
-
Montpellier CHU Saint Eloi
Montpellier, France
-
Nantes CHU Hotel Dieu
Nantes, France
-
Nocera
Nocera Umbra, Italy
-
Ospedale Infermi Ematologia Rimini
Rimini, Italy
-
Paris Hopital Saint Louis
Paris, France
-
Pierre Bénite CHU Lyon Sud
Lyon, France
-
Rennes CHU Pontchaillou
Rennes, France
-
Rouen Centre Henri Becquerel
Rouen, France
-
SC Ematologia Torino-Molinette
Torino, Italy
-
SC Oncoematologia Terni
Terni, Italy
-
Torino Università, Ematologia 1, AO Città della Salute e della Scienza
Torino, Italy
-
Tours CHU Bretonneau
Tours, France
-
UO Ematologia Ravenna
Ravenna, Italy
-
Vandoeuvre lès Nancy CHU Brabois
Nancy, France
Conditions
Explore the condition pages connected to this study.